Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study

Journal of Dermatological Treatment

Volumn 26, Issue 4, 2015, Pages 318-325

  Belinchon I ^a   Vanaclocha, F ^b   De La Cueva Dobao, P ^c   Coto Segura, P ^d   Labandeira, J ^e   Herranz, P ^f   Taberner, R ^g   Julia B ^h   Cea Calvo, L ^h   Puig, L ⁱ  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e University Hospital of Santiago de Compostela   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL SON LLÀTZER   (Spain)

^h Medical affairs Merck sharp and Dohme ltd   (Spain)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Cardiovascular disease; metabolic syndrome; prevalence; psoriasis

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTICENTER STUDY; OBESITY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; SEDENTARY LIFESTYLE; SPAIN; SYSTEMIC THERAPY; WAIST CIRCUMFERENCE; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; RISK FACTOR;

ADULT; AGED; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREVALENCE; PSORIASIS; RISK FACTORS; SPAIN;

EID: 84939160156     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2014.983039     Document Type: Article

References (34)

1. Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145:379-82.
2. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006; 55:829-35.
3. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31: 1000-6.
4. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
5. Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013; 27:12-29.
6. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and metaanalysis of observational studies. J Am Heart Assoc. 2013;2: e000062.
7. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73.
8. Love TJ, Qureshi AA, Karlson EW, et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;147:419-24.
9. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132:556-62.
10. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013;68:654-62.
11. Vanaclocha F, Belinchón I, Sánchez-Carazo JL, et al. Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-risk, descriptive study. Eur J Dermatol 2014 [Epub ahead of print]. doi:10.1684/ ejd.2014.2440.
12. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
13. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321-8.
14. Miller IM, Ellervik C, Yazdanyar S, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69:1014-24.
15. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol. 2010;24:23-30.
16. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149:84-91.
17. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and metaanalysis of observational studies. J Hypertens. 2013;31:433-42.
18. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and metaanalysis of observational studies. Nutr Diabetes. 2012;2:e54.
19. Guallar-Castillón P, Pérez RF, López Garća E, et al. Magnitude and management of metabolic syndrome in Spain in 2008-2010: the ENRICA Study. Rev Esp Cardiol. 2014;67:367-73.
20. Fernández-Bergés D, Cabrera de León A, Sanz H, et al. Metabolic syndrome in Spain: prevalence and coronary risk associated with harmonized definition and WHO proposal. DARIOS study. Rev Esp Cardiol (Engl Ed). 2012;65:241-8.
21. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. JAMA. 2002;288:2709-16.
22. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145:700-3.
23. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011; 124:775.e1-6.
24. Mattsson N, Rönnemaa T, Juonala M, et al. Arterial structure and function in young adults with the metabolic syndrome: the Cardiovascular Risk in Young Finns Study. Eur Heart J. 2008;29: 784-91.
25. Kondo T, Osugi S, Shimokata K, et al. Metabolic syndrome and allcause mortality, cardiac events, and cardiovascular events: a followup study in 25,471 young-and middle-aged Japanese men. Eur J Cardiovasc Prev Rehabil. 2011;18:574-80.
26. Kimball AB, Szapary P, Mrowietz U, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;67:76-85.
27. Belinchon I, Vanaclocha F, Jimenez-Puya R, et al. Underdiagnosis of cardiovascular risk factors in patients with psoriasis under systemic therapy in Spain. Pso-risk study [abstract no. P082]. J Eur Acad Dermatol Venereol. 2013;27:35.
28. Puig L, Strohal R, Husni ME, et al. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. J Dermatolog Treat. 2013. [Epub ahead of print].
29. Carretero G, Ribera M, Belinchón I; Psoriasis Group of the AEDV. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104:598-616.
30. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;(1):CD007893.
31. Puig L. Anti-tumour necrosis factor - A treatment and weight gain in psoriasis: the 'pudgy blanching' conundrum. Br J Dermatol. 2013; 168:923-4.
32. Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors. Am J Clin Dermatol. 2014;15:45-50.
33. Nguyen T, Wu JJ. Relationship between tumor necrosis factor - A inhibitors and cardiovascular disease in psoriasis: a review. Perm J. 2014;18:49-54.
34. Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014;105:31-44.